Organization
Hangzhou HighField Biopharmaceuticals Corporation
4 abstracts
Abstract
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.Org: Hangzhou HighField Biopharmaceuticals Corporation, Zhejiang University, School of Pharmacy,
Abstract
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy.Org: Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Zhejiang University, Hangzhou, China,
Abstract
Modulating MDSCs by HF1K16: A mono-therapy phase Ia study examining safety and preliminary efficacy in patients with refractory and metastatic cancer.Org: Hangzhou Highfield Biopharmaceuticals Inc., Zhejiang University, School of Pharmacy, Hua Shan Hospital, Department of Clinical Pharmacy & Pharmacology, UMCG, Groningen, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China,
Abstract
T cell redirecting and TLR7/8 agonist encapsulated liposomes targeting HER2+ tumors: Preclinical efficacy, pharmacokinetics and safety evaluations.Org: Hangzhou Highfield Biopharmaceuticals Inc., Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences,